KRAS and lung adenocarcinoma: As over one-third of lung adenocarcinomas harbour KRAS mutations, KRAS is therefore an important biomarker that might be used in monitoring treatment, as a biomarker for relapse/progression (disease monitoring), and as a prognostic biomarker.